Brent  Sabatini net worth and biography

Brent Sabatini Biography and Net Worth

Brent Sabatini is the CAO of Vir Biotechnology. They are 52 years old.

What is Brent Sabatini's net worth?

The estimated net worth of Brent Sabatini is at least $374.84 thousand as of February 13th, 2026. Sabatini owns 47,872 shares of Vir Biotechnology stock worth more than $374,838 as of February 19th. This net worth estimate does not reflect any other investments that Sabatini may own. Learn More about Brent Sabatini's net worth.

How do I contact Brent Sabatini?

The corporate mailing address for Sabatini and other Vir Biotechnology executives is 499 ILLINOIS STREET SUITE 500, SAN FRANCISCO CA, 94158. Vir Biotechnology can also be reached via phone at 415-906-4324 and via email at [email protected]. Learn More on Brent Sabatini's contact information.

Has Brent Sabatini been buying or selling shares of Vir Biotechnology?

During the past quarter, Brent Sabatini has sold $11,918.70 in shares of Vir Biotechnology stock. Most recently, Brent Sabatini sold 1,530 shares of the business's stock in a transaction on Friday, February 13th. The shares were sold at an average price of $7.79, for a transaction totalling $11,918.70. Following the completion of the sale, the chief accounting officer now directly owns 47,872 shares of the company's stock, valued at $372,922.88. Learn More on Brent Sabatini's trading history.

Who are Vir Biotechnology's active insiders?

Vir Biotechnology's insider roster includes Marianne De Backer (CEO & Director), Vanina de Verneuil (EVP, General Counsel and Corporate Secretary), Mark Eisner (Executive Vice President and Chief Medical Officer), Ann Hanly (CTO), Howard Horn (CFO), Robert More (Director), Janet Napolitano (Director), Jason O'Byrne (Executive Vice President and Chief Financial Officer), Phillip Pang (Insider), Jay Parrish (Insider), Saira Ramasastry (Director), Steven Rice (Insider), Brent Sabatini (CAO), Vicki Sato (Director), George Scangos (CEO), and Herbert Virgin (EVP). Learn More on Vir Biotechnology's active insiders.

Are insiders buying or selling shares of Vir Biotechnology?

In the last twelve months, insiders at the sold shares 38 times. They sold a total of 3,243,863 shares worth more than $19,550,428.41. The most recent insider tranaction occured on February, 13th when CAO Brent Sabatini sold 1,530 shares worth more than $11,918.70. Insiders at Vir Biotechnology own 16.0% of the company. Learn More about insider trades at Vir Biotechnology.

Information on this page was last updated on 2/13/2026.

Brent Sabatini Insider Trading History at Vir Biotechnology

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/13/2026Sell1,530$7.79$11,918.7047,872View SEC Filing Icon  
2/13/2025Sell1,562$9.15$14,292.3028,189View SEC Filing Icon  
See Full Table

Brent Sabatini Buying and Selling Activity at Vir Biotechnology

This chart shows Brent Sabatini's buying and selling at Vir Biotechnology by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Vir Biotechnology Company Overview

Vir Biotechnology logo
Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $7.62
Low: $7.50
High: $7.86

50 Day Range

MA: $6.69
Low: $5.76
High: $7.83

2 Week Range

Now: $7.62
Low: $4.16
High: $9.97

Volume

232,814 shs

Average Volume

1,753,891 shs

Market Capitalization

$1.06 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.69